LONDON, February 1, 2018 /PRNewswire/ --

Forecasts and Analysis by Therapeutic Class (Oncology, Alimentary Tract & Metabolism, Hormonal Disorders & Haematology, Neuroscience, Respiratory, Cardiovascular, Nephrology and Ophthalmology), Drug Class (Biologic, Small Molecule) & by Region Plus Analysis of Leading Companies

Report Details 

• Do you need definitive Orphan Drugs market data?
• Succinct Orphan Drugs market analysis?
• Technological insight?
• Actionable business recommendations?

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

Read on to discover how this definitive report can transform your own research and save you time. 

The Global Orphan Drugs market shows immense potential to grow in the future, growing in line with some emerging trends. One such trend is the increasing strategic partnerships in a move to introduce or diversify product portfolios pertaining to drugs. Another trend is advances in biomedical sciences and introduction of nanotechnologies in the global pharmaceutical market, which are revolutionising the development of medicines.

Lastly, the study of the pathogenesis of disease at genetic and molecular level studies have led to the discovery of new targets for therapy and producing disease modifying drugs.

Report highlights 

• 149 quantitative tables, charts, and graphs across 173 pages 

• Global Orphan Drugs market outlook and analysis from 2018-2028 

• Global Orphan Drugs submarket forecasts and analysis from 2018-2028
• Oncology
• Alimentary Tract & Metabolism
• Hormonal Disorders & Haematology
• Neuroscience
• Respiratory
• Cardiovascular
• Nephrology

• Key National Orphan Drugs market forecasts 2018-2028
• US forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• Japan forecast 2018-2028
• Singapore forecast 2018-2028
• South Korea forecast 2018-2028
• Brazil forecast 2018-2028
• Russia forecast 2018-2028
• China forecast 2018-2028
• Brazil forecast 2018-2028

Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to Orphan Drugs
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO's
• CIO's
• COO's
• Business development managers
• Investors
• Governments
• Agencies
• Banks

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com (+44-(0)-20-7336-6100) or refer to our website: https://www.visiongain.com/Report/2113/Orphan-Drugs-Market-Report-2018-2028

Companies Mentioned in the Report 

Acorda Therapeutics

ABBVIE INC

AbbVie Ltd

Actelion Pharmaceuticals

Advanced Accelerator Applications

Aegerion Pharmaceuticals

Alexion

Amgen

Amicus Therapeutics UK Ltd

Arbor Pharmaceuticals LLC

AstraZeneca

AVEDRO INC

Baxalta Innovations GmbH

Baxter International

Bayer

Bio Products Laboratory Ltd

Biogen Idec Ltd

Biomarin

Bioprojet Pharma

Boehringer Ingelheim Pharmaceuticals, Inc.

Bristol-Myers Quibb

Celgene

Clovis Oncology Inc

CSL Behring GmbH

EISAI INC

Eli Lilly And Company

Eli Lilly Nederland B.V.

Elusys Therapeutics, Inc

Genentech, Inc

GlaxoSmithKline Trading Services Limited

Intercept Pharmaceuticals Inc

Janssen Pharmaceuticals Inc

Janssen-Cilag International N.V.

Jazz Pharmaceuticals Inc

Lundbeck Llc

Merck

Millennium Pharmaceuticals

Mitsubishi Tanabe Pharma Corporation

MolMed SpA

Navidea Biopharmaceuticals

Nova Laboratories Limited

Novarits

Novatech SA

Novo Nordisk Inc.

NX Development Corporation

Onyx Therapeutics Inc.

Otsuka Pharmaceutical

Pfizer

Pharmacyclics

Pharming Group

Pierre Fabre Dermatologie

Provepharm

Provepharm

PTC Therapeutics

Rare Disease Therapeutics

Retrophin

Roche

Sarepta Therapeutics

Seattle Genetics

Shire-NPS Pharmaceuticals

Silvergate Pharmaceuticals

Spectrum Pharmaceuticals

Strongbridge

Swedish Orphan Biovitrum AB

Takeda Pharma

Tesaro

Teva Pharmaceuticals

United Therapeutics Corporation

Vanda Pharmaceuticals

Veloxis Pharmaceuticals

Vertex Pharmaceuticals

Wellstat Therapeutics

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

SOURCE Visiongain